# OnCo record full-life-technologies (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/full-life-technologies/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "full-life-technologies" ;
  schema:name "Full-Life Technologies"@en ;
  schema:description "Full-Life Technologies makes medicines that carry a strongly radioactive particle, actinium-225, onto cancer cells so the radiation acts at short range. Its lead medicine is being tested in advanced prostate cancer and a second in lung and other solid tumours."@en ;
  schema:url <https://onco.cc/companies/full-life-technologies/>, <https://www.full-life.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.full-life.com/>, <https://www.full-life.com/about-us>, <https://www.full-life.com/radio/pipeline>, <https://www.full-life.com/media/press-releases>, <https://clinicaltrials.gov/study/NCT06492122>, <https://clinicaltrials.gov/study/NCT07873450> ;
  schema:addressCountry "CN" ;
  onco:cancers <https://onco.cc/cancers/prostate-mcrpc/>, <https://onco.cc/cancers/nsclc/> ;
  onco:sections <https://onco.cc/fronts/radiopharma/> ;
  onco:technologies <https://onco.cc/technologies/targeted-alpha-therapy/>, <https://onco.cc/technologies/radioligand-therapy/>, <https://onco.cc/technologies/actinium-225-supply/> ;
  onco:targets <https://onco.cc/targets/psma/>, <https://onco.cc/targets/met/> .